
Aptevo (APVO) has disclosed a new risk, in the Regulation category. Aptevo benefits from an existing orphan drug designation, but this status neither accelerates development nor regulatory review, and it
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| APVO | Aptevo Therapeutics | 0.46 | -23.30 | -98.06% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.46 | -98.06% |

Aptevo (APVO) has disclosed a new risk, in the Regulation category. Aptevo benefits from an existing orphan drug designation, but this status neither accelerates development nor regulatory review, and it

Q3 Business Highlights: Mipletamig delivers a 79% remission rate in one of the hardest-to-treat forms of AML, nearly double a published historical benchmark; Ten of 47 patients receiving mipletamig combination

Aptevo Therapeutics ( ($APVO) ) just unveiled an announcement. On November 11, 2026, Aptevo entered agreements with certain warrant holders who agreed to exercise existing warrants for up to 2,777,778

Aptevo Therapeutics (APVO) has entered into warrant inducement letter agreements with certain holders of its existing common warrants, pursuant to which such holders have agreed to exercise in full for

Aptevo Therapeutics ( ($APVO) ) just unveiled an update. On November 7, 2026, Aptevo presented new preclinical data from its next-generation multispecific platform at SITC 2026, showing that APVO451 and

Aptevo Therapeutics (APVO) announced that on November 7, 2026, the Company presented new preclinical data from its next-generation multispecific platform at the Society for Immunotherapy of Cancer, SITC, 2026 Annual

Aptevo Therapeutics ( ($APVO) ) has provided an update. On November 5, 2026, Aptevo announced that successive refinements to mipletamig’s priming-dose regimen substantially reduced infusion-related reactions in frontline AML. The

Aptevo Therapeutics (APVO) announced an important clinical development milestone for mipletamig: a substantial reduction in infusion-related reactions, IRRs, following successive refinements to its priming-dose regimen. The improvement builds on mipletamig’s

Aptevo Therapeutics ( ($APVO) ) just unveiled an update. On October 26, 2026, Aptevo reported that ten of forty-seven frontline acute myeloid leukemia patients initially considered unfit for intensive chemotherapy

Aptevo Therapeutics (APVO) announced that ten patients with newly diagnosed acute myeloid leukemia, AML, have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Sep 3, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $1.60M | ― | ― | 0.00 | -0.00 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.